Governance BeiGene, Ltd.

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 14/09/2024 am IST			5-day change	1st Jan Change
198.49 ^USD	+1.13%		+3.75%	+10.05%

12/09	Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	MT
11/09	Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	MT

Executive Committee: BeiGene, Ltd.

Manager

Positions heldSince

John Oyler

56 year

Chief Executive Officer	28/10/2010
Founder	28/10/2010

Kyu-Sung Lee

64 year

Chief Tech/Sci/R&D Officer

01/01/2022

Chan Lee

General Counsel

18/07/2022

Graham Hardiman

Human Resources Officer

01/01/2021

Christiane Langer

Chief Tech/Sci/R&D Officer

01/08/2021

Lai Wang

47 year

Chief Tech/Sci/R&D Officer

01/04/2021

Yan Liu

Sales & Marketing

01/06/2019

Liza Heapes

Investor Relations Contact

Xiao Bin Wu

62 year

Chief Operating Officer	01/04/2021
President	01/04/2018

Scott Samuels

54 year

Corporate Secretary

Wendy Yan

58 year

General Counsel

01/08/2014

Titus Ball

51 year

Comptroller/Controller/Auditor

01/08/2023

Composition of the Board of Directors: BeiGene, Ltd.

Director

CommitteesSince

John Oyler

56 year

Chairman

27/01/2016

Anthony Hooper

69 year

Audit Committee	01/01/2020
Compensation Committee Chair
Governance Committee	01/01/2020
Nominating Committee	01/01/2020
Audit Committee Chair	13/09/2023

Corazon Sanders

67 year

Compensation Committee
Governance Committee	01/08/2023
Nominating Committee	01/08/2023
Audit Committee

Michael Goller

49 year

Governance Committee	01/04/2015
Nominating Committee	01/04/2015
Governance Committee Chair	21/10/2015
Nominating Committee Chair	21/10/2015

Alessandro Riva

63 year

Governance Committee	01/02/2022
Nominating Committee	01/02/2022
Audit Committee	01/05/2021

Olivier Brandicourt

68 year

Audit Committee	22/01/2024
Compensation Committee	02/03/2020
HR Committee	02/03/2020

Donald Glazer

79 year

Governance Committee Chair	01/02/2013
Nominating Committee Chair	01/02/2013

Ranjeev Krishana

50 year

Compensation Committee

01/10/2014

Qing Qing Yi

52 year

Compensation Committee

Margaret Dugan

67 year

Compensation Committee Chair

01/02/2022

Xiao Dong Wang

61 year

Director/Board Member

01/02/2016

Latest Appointments: BeiGene, Ltd.

BeiGene Appoints CFO	18/07	MT
BeiGene Names Aaron Rosenberg CFO	18/07	MT
BeiGene Names Rosenberg Finance Chief as Wang Departs	18/07	DJ
Beigene, Ltd. Appoints Aaron Rosenberg as the Principal Financial Officer, Effective from July 22, 2024	18/07	CI
BeiGene, Ltd. Announces Executive Changes	21/03	CI
Beigene, Ltd. Announces Board Changes	23/01	CI
BeiGene, Ltd. Announces Board Changes	23/01	CI

More news

Former Officers and Directors: BeiGene, Ltd.

Insider

Positions held

SinceUntil

Julia Wang

Comptroller/Controller/Auditor	30/06/2021	19/03/2024
Director of Finance/CFO	30/06/2021	19/07/2024
Corporate Officer/Principal	01/06/2020	30/06/2021

Thomas Malley

Director/Board Member	01/01/2016	22/01/2024
Independent Dir/Board Member	01/01/2016	22/01/2024

Kate Corcoran

Private Equity Investor

01/09/2023

Bob Mecca

Corporate Officer/Principal

01/06/2021

01/07/2023

Mark Mossler

Comptroller/Controller/Auditor

01/05/2017

01/06/2023

Yung Cheng Chen

Director/Board Member	08/02/2016	22/06/2022
Independent Dir/Board Member	08/02/2016	22/06/2022

Jane Huang

Chief Tech/Sci/R&D Officer

06/09/2016

03/04/2022

Bernd Kullmann

Corporate Officer/Principal

01/01/2021

01/04/2022

Yong Ben

Chief Tech/Sci/R&D Officer	01/02/2019	-
Corporate Officer/Principal	-	-

sam Su

Director/Board Member	03/04/2018	31/01/2022
Independent Dir/Board Member	03/04/2018	31/01/2022

Kevin C. Mannix

Investor Relations Contact

01/12/2021

Lucy Li

Investor Relations Contact

01/12/2021

Howard Liang

Director of Finance/CFO

01/07/2015

30/06/2021

Craig West

Investor Relations Contact

01/05/2018

01/03/2021

Michael Zimmerman

Director/Board Member

01/07/2013

31/12/2020

Angus J. Grant

Corporate Officer/Principal

01/07/2020

Andrea Pirzkall

Chief Tech/Sci/R&D Officer

01/08/2017

01/07/2020

Yi Fei Zhu

Corporate Officer/Principal

01/04/2018

01/03/2019

Yi Fei Zhu

Sales & Marketing

01/03/2019

Amy Peterson

Chief Tech/Sci/R&D Officer	24/08/2016	23/01/2019
Corporate Officer/Principal	24/08/2016	-

Ji Li

Director/Board Member	01/01/2015	-
Corporate Officer/Principal	04/05/2016	30/04/2018

Michael Garvey

Chief Tech/Sci/R&D Officer

01/01/2018

Alice Kang

Chief Tech/Sci/R&D Officer	-	-
Corporate Officer/Principal	-	01/08/2017

Ke Tang

Director/Board Member

01/10/2014

01/06/2017

Todd Yancey

Chief Tech/Sci/R&D Officer	01/01/2017	-
Corporate Officer/Principal	-	-

Jian Xin Yang

Chief Tech/Sci/R&D Officer

01/07/2014

01/12/2016

Ross Pettit

Corporate Officer/Principal

03/10/2016

Eric Hedrick

Chief Tech/Sci/R&D Officer	01/06/2015	24/08/2016
Chief Tech/Sci/R&D Officer	23/01/2019	-

Ruirong Yuan

Chief Tech/Sci/R&D Officer

01/11/2015

11/04/2016

Tai Ching Ho

Founder	01/10/2010	01/12/2012
President	01/10/2010	01/12/2012

Pearl Shirley Huang

Chief Tech/Sci/R&D Officer	01/01/2010	01/01/2012
Founder	01/01/2010	01/01/2012

Maggie Liu

Chief Operating Officer

Maryline Iva

Public Communications Contact

Denise Dettore

Corporate Officer/Principal

Xiao Jun Yan

General Counsel

Xin Bian

Sales & Marketing

Cherry Thomas

Chief Tech/Sci/R&D Officer

Age distribution of managers

Parity Men Women

Male	24
Female	4

Of which Executive Committee

Male	10
Female	2

Of which Directors

Male	11
Female	0

ESG Refinitiv

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Employees

10,000

Sector

Biotechnology & Medical Research

Calendar

07/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Governance BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Executive Committee: BeiGene, Ltd.

Composition of the Board of Directors: BeiGene, Ltd.

Latest Appointments: BeiGene, Ltd.

Former Officers and Directors: BeiGene, Ltd.

Age distribution of managers

Parity Men Women

Environment

Social

Governance

Controversy

Company Profile